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Summary 
Aviator Xpro EC 225 containing the active substance bixafen was assessed by VKM in spring 
2013, and it was concluded that the metabolite M44 has potential for groundwater 
contamination. Furthermore, VKM assessed in late 2013 the relevance of this metabolite in 
accordance with the EU guidance document on metabolites in groundwater, and concluded 
that the malformations observed in rabbits exposed to the metabolite should be considered 
treatment related. VKM also concluded that the data presented to evaluate the possible 
genotoxic properties of the metabolite was insufficient to reach a conclusion. Based on this, 
the Norwegian Food Safety Authority rejected the approval of Aviator Xpro EC 225. 
The applicant has now submitted results from an in vivo study to strengthen the basis for 
assessment of genotoxic properties, and also submitted new historical controls in relation to 
the experimental studies on foetal developmental effects in rabbits. The VKM Panel on Plant 
Protection Products has discussed the questions raised by The Norwegian Food Safety 
Authority on the basis of the new data, and has the following opinion:   
On the assessment of genotoxic properties of the M44 metabolite of bixafen, one 
of the active ingredients of Aviator Xpro EC 225  
It is the view of VKM Panel on Plant Protection Products that the new in vivo mouse 
micronucleus study, supplemented together with a separate study demonstrating 
bioavailability, overrides the results of the in vitro clastogenicity studies. Taken together, it is 
the opinion of VKM that under the conditions studied, M44 should be considered as non-
genotoxic. 
On the assessment of the relevance of the foetal malformations in M44 exposed 
animals 
VKMs Panel on Plant Protection products has assessed the arguments and new historical 
control data presented by the applicant, intended to show that metabolite M44 is not 
teratogenic. It is however the opinion of the Panel that the arguments and the new historical 
data provided by the applicant do not alter the panel’s previous conclusion; that the 
malformations observed in rabbits exposed to the metabolite M44 should be considered 
treatment related.    
 
 
Key words: VKM, risk assessment, Norwegian Scientific Committee for Food Safety, 
pesticide, ground water, Aviator, bixafen, metabolite, M44 
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Sammendrag på norsk 
Aviator Xpro EC 225 med det virksomme stoffet bixafen ble vurdert av VKM våren 2013, og 
det ble konkludert med at metabolitten M44 har potensiale for grunnvanns-forurensning. 
Senere samme år konkluderte VKM med at misdannelser observert hos kanin bør ansees å 
være knyttet eksponering for metabolitten. VKM var også av den oppfatning at dataene for å 
vurdere om metabolitten kan skade arvematerialet var utilstrekkelige. Basert på dette avslo 
Mattilsynet å godkjenne Aviator Xpro EC 225 for bruk i Norge. 
Søker har nå levert nye resultater fra en in vivo studie for øke grunnlaget for å kunne 
vurdere om metabolitten kan ha arvestoffskadelige egenskaper, og dessuten nye historiske 
kontroller til å supplere studiene av fostereffekter i kanin. VKMs Faggruppe for 
plantevernmidler har diskutert spørsmålene som reises av Mattilsynet på bakgrunn av søkers 
klage, og har følgende konklusjon: 
Vurdering av arvestoffskadelige egenskaper hos metabolitten M44  
VKMs Faggruppe for plantevernmidler er av den oppfatning at det ny-innsendte forsøket, et 
in vivo mus mikrokjerneforsøk, sammen med måling av stoffets biotilgjengelighet, gjør at 
M44 ikke anses å være arvestoff-skadelig. 
Vurdering av misdannelser i kaniner eksponert for M44 
VKMs Faggruppe for plantevernmidler har vurdert søkers argumenter og nye historiske 
kontrolldata, som er ment å vise at metabolitten M44 er ikke har fosterskadelige effekter. 
VKM er imidlertid av den oppfatning at argumentene og de nye historiske dataene fra søker 
ikke endrer faggruppens tidligere konklusjon; at foster-misdannelser observert hos kanin 
eksponert for metabolitten M44 synes å være resultat av eksponeringen for M44. 
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Abbreviations  
DMSO  dimethyl sulfoxide 
In vivo  Experiment on living organisms 
In vitro “In glass” – experiment outside an organism – in test tube 
NOAEL  No Observed Adverse Effect Level 
VKM  Norwegian Scientific Committee for Food Safety 
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Background as provided by the 
Norwegian Food Safety Authority 
The new plant protection product Aviator Xpro EC 225 containing the new active substance 
bixafen was assessed by the VKM in spring 2013 (VKM, 2013a). In the VKM assessment of 
environmental fate and behavior, it was concluded that a metabolite coded M44 has 
potential for groundwater contamination in concentration above 0.1 µg/L. The Norwegian 
Food Safety Authority therefore asked the VKM to assess the relevance of this metabolite in 
accordance to the "Guidance Document on the Assessment of the Relevance of Metabolites 
in Groundwater of Substances Regulated Under Council Directive 91/414/EEC" (European 
Commission, 2003). VKM assessed the relevance of this metabolite in December 2013, and 
concluded that the "misshapen interparietal bone" and the "severely malformed vertebral 
column and/or ribs" should be considered treatment related (VKM, 2013b). Based on the 
VKM conclusion, the Norwegian Food Safety Authority rejected the approval of Aviator Xpro 
EC 225. 
In the VKM relevance assessment of the bixafen groundwater metabolite M44 in December 
2013, VKM concluded that the presented data from in vitro experiments did not provide the 
necessary assurance that metabolite M44 was negative for genotoxic activity (VKM, 2013b). 
No data for in vivo testing of the metabolite was presented for the VKM evaluation in 2013. 
However, the applicant has later submitted an in vivo genotoxicity study to confirm that the 
metabolite M44 is negative in terms of genotoxicity.  
 
Terms of reference as provided by the 
Norwegian Food Safety Authority 
The applicant has filed an appeal against the Norwegian Food Safety Authority's decision to 
reject the approval of Aviator Xpro EC 225. The applicant has provided new historical control 
data for the above-mentioned findings of foetal malformations. The Norwegian Food Safety 
Authority asks VKM to assess whether the arguments and the new historical control data 
presented by the applicant give reason to revoke the decision on metabolite M44 with 
regards to its ability to induce foetal malformations, and whether the newly submitted 
genotoxicity study provides the necessary assurance for concluding on the non-genotoxicity 
of metabolite M44. 
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Assessment 
1 Introduction 
Aviator Xpro EC 225 containing the active substance bixafen was assessed by VKM in 2013 
(VKM, 2013a). In this assessment it was concluded that the metabolite M44 had properties 
which suggested a potential for groundwater contamination above the concentration of 0.1 
µg/L. Based on this, The Norwegian Food Safety Authority requested VKM to assess this 
metabolite in accordance with the "Guidance Document on the Assessment of the Relevance 
of Metabolites in Groundwater of Substances Regulated under Council Directive 91/414/EEC" 
(Sanco/221/2000-rev.10-final, 25 February 2003) (European Commission, 2003). This was 
done in a meeting in December 2013, and VKM concluded that the finding of "misshapen 
interparietal bone" and "severely malformed vertebral column and/or ribs" should be 
considered treatment related (VKM, 2013b). Based on this conclusion, the Norwegian Food 
Safety Authority did not approve the application for registration of Aviator Xpro EC 225 in 
Norway. 
Following the rejection, the applicant filed an appeal against the Norwegian Food Safety 
Authority's decision not to approve the registration of Aviator Xpro EC 225 for use in Norway. 
In the appeal the applicant included additional historical control data linked to the reported 
findings of malformations in the reproduction studies. The Norwegian Food Safety Authority 
has requested an opinion from VKM whether the new historical control data and the 
arguments presented by the applicant are sufficient to alter the previous conclusion 
regarding the above mentioned foetal malformations observed in animal experiments 
following exposure to the metabolite M44. 
VKM’s assessment is based on the Norwegian Food Safety Authority’s evaluation of the 
documentation submitted by the applicant.  
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2 Hazard identification and 
characterisation  
2.1 Summary of VKMs view on adverse test findings 
VKM had in its previous report the following conclusions regarding the presented test results 
for bixafen and the metabolite M44: 
 Bixafen 2.1.1
The liver effects and effects on coagulating parameters were considered adverse and of 
relevance to humans. 
The thyroid follicular cell tumours reported in female rats were not considered sufficient to 
suggest that bixafen had a tumour inducing potential. 
The presented data was not considered sufficient to exclude that the observed reduction in 
pup weight and increased number of stillborn pups in the F1 and F2 generation were induced 
by bixafen. 
The reported pup developmental effects were considered treatment related, and not 
regarded as secondary effects to maternal toxicity. 
 Metabolite M44 2.1.2
The in vitro experiments on genotoxicity were not considered to provide sufficient assurance 
that the bixafen metabolite M44 was negative for genotoxic activity. 
The foetal malformations («misshapen intraparietal bone» and «severely malformed 
vertebral columns and/or ribs») were considered treatment related. 
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2.2 Re-assessment of the relevance of the foetal malformations 
in M44 exposed animals 
The applicant has appealed the decision and has presented arguments and new historical 
control data, to show that metabolite M44 is not teratogenic. 
 The applicant’s arguments for why the metabolite M44 should not 2.2.1
be regarded as teratogenic 
2.2.1.1 «Misshapen interparietal bone» 
The applicant argues that «misshapen interparietal bone» has a high natural occurrence in 
the rabbit line and shows that 10 of 38 skeletal malformations were «misshapen interparietal 
bone» in the historical control data. The applicant claims that this deformity occurs randomly 
because of the comparable incidence in both control and dose groups in other teratology 
studies at the same lab using the same rabbit line.  
2.2.1.2 “Severely malformed vertebral column and/or ribs” 
The applicant disagrees with VKMs statement that "the lack of a dose-response relationship 
for this effect could be masked by the increased maternal mortality at the highest dose 
level." The applicant argues that there is no relationship between maternal toxicity and 
“severely malformed vertebral column and/or ribs”, and that the absence of such a 
relationship makes it very unlikely that the increased maternal mortality will mask a dose-
response relationship. Furthermore, the number of litters with live foetuses is comparable in 
middle (17 litters) and highest (18 litters) dose group, suggesting that the occurrence of the 
abnormality should increase in the highest dose group despite increased maternal mortality. 
The applicant has also summarized a number of authorities that have considered the 
increased incidence of "severely malformed vertebral columns and / or ribs" in the middle 
dose group as random and not treatment related, because of lack of dose-response. 
 VKM’s opinion on the observed effects in rabbit foetuses following 2.2.2
exposure of the mother animal to M44  
Despite the comparable number of litters in middle and highest dose group, the number of 
foetuses is still lower in the highest dose group. Furthermore, despite increased number of 
abortions in the highest dose group, the aborted foetuses were not examined for skeletal 
malformations, and thus it is not possible to assess whether abortions were associated with 
skeletal malformations in the highest dose group. However, the Canadian Pest Management 
Regulatory Agency (PMRA) established a developmental NOAEL of 300 mg / kg bw / day 
from this study, based on the increase in the number of abortions (http://www.hc-
sc.gc.ca/ahc-asc/branch-dirgen/pmra-arla/index-eng.php). Likewise, the increase in the 
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number of abortions is also assumed to be treatment-related by the manufacturer but 
related to the general toxicity of the females in the highest dose group. 
 VKM’s opinion on the observed effect of M44 on rabbit foetuses in 2.2.3
light of the new historical control data  
2.2.3.1 The use of historical control data 
Due to limited numbers of unexposed control animals in each experimental study, and often 
only one or two experiments performed for each pesticide, values for untreated animals from 
other experiments (so-called historical controls) have been used to strengthen the findings in 
individual experiments. A number of requirements must however be fulfilled in order to use 
other data than the data from the actual test experiment of the relevant pesticide 
2.2.3.2 Quality of historical control data 
There are a number of requirements for the quality and use of historical control, for example 
illustrated by the British Health and Safety Excecutive (HSE, 2004), and in in Annex 1, 
section 5.5 or 5.6 of Directive 94/79/EC (European Commission, 1994). 
According to the guidelines, historical control data should be from studies that are identical 
or closely related to the study under consideration. The historical control data should not be 
more than +/- two years compared with the current study, and studies must partly be 
performed with the same species and animal line, at the same lab and under comparable 
condition. 
The historical data should also be presented on a study by study basis, or at least should 
detailed data on the variation of the historical controls be presented, such as the range of 
values, the mean, median and, if applicable, standard deviation.  
The submitted historical control data should be from studies that are identical or closely 
related to the study under consideration in terms of: 
1. Species, strain and supplier.  
2. Test facility.  
3. Housing conditions (single or multiple) and diet.  
4. Survival rates (especially for carcinogenicity studies).  
5. Date of performance - typically +/- two years. Values and incidences vary with time 
and it is essential to have information on studies performed within a relatively short time 
period. Although retrospective data will only be available at the time of writing a study 
report, additional studies will normally be available by the time a dossier is submitted. The 
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more recent data are particularly relevant and should be submitted. Periods greater than +/- 
2 years might be justifiable if the test facility does not perform the particular study type 
routinely.  
6. Assessment criteria (e.g. terminology / definitions for histopathology and 
developmental findings or clinical chemistry assay methodology).  
7. Age or weight of animals at initiation of study and / or the time of investigation 
(especially for short-term studies).  
8. Group size.  
9. Dose route. The submission must provide adequate supporting information to permit 
independent confirmation of the applicability of the historical control data, based on the 
above criteria. There should also be a statement that the data cover all appropriate studies 
performed by the test facility during the period under consideration, and have not been 
selected in any way.  
There is no guarantee that historical control data that meet the criteria defined above will be 
used in an assessment. For example where pre-dosing data, or incidences in lower dose 
groups, are consistent with the concurrent controls the assumption would be that the 
concurrent controls are truly representative of the background levels pertaining at the time 
of the study. 
2.2.3.3 “Old” and “New” historical control  
The teratology study in rabbits with the metabolite M44 performed in 2008 was the first 
study using New Zealand White Rabbits in BASF Toxicological Laboratory. The applicant 
claims that the previously submitted historical control data should be replaced by new data 
because the old historical controls were based on four studies performed 7 and 9 years 
earlier. The applicant argues that the new submitted data is more relevant because they 
were performed in a period closer to the current study and because the same rabbit line 
(NZW rabbits) was used. However, the new historical control data does not fulfil all the 
requirements of the guidelines because some of the studies are up to 8 years younger than 
the M44 teratology study, and in June 2013 there was a shift in the supply of laboratory 
animals. 
The new historical control data presented by the applicant is indicated in Table 2.2.3.3-1 and 
2.2.3.3-2. The tables summarizes the incidence of malformations in the M44 teratology 
study, as well as the occurrence of these malformations in the "new" and "old" historical 
control data. As indicated in the tables, the occurrence of "misshapen interparietal bone" in 
teratology metabolite M44 of 1.9%, the occurrence of this malformation is beyond even the 
new historical control data.   
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Table 2.2.3.3-1.  Incidence of «misshapen interparietal bone». Study with M44 and historical 
controls. *: statistically different from control. 
Year Fetal incidence (n/tot) Affected fetuses/litter (%) 
 control Low 
dose 
Mid 
dose 
High 
dose 
control Low 
dose 
Mid 
dose 
High 
dose 
2009 1/351 1/153 1/152 3/138 0.2 0.6 0.4 1.9* 
         
2009 3/184    1.2    
2009 2/156    0.6    
2010 1/251    0.6    
2010 0/189    0    
2011 2/232    1.4    
2012 2/150    0.9    
2012 0/214    0    
2012 0/125    0    
2013 0/194    0    
2013 0/154    0    
2013 0/186    0    
2013 0/126    0    
2014 0/234    0    
Historical 
controls 
10/2395        
 
Table 2.2.3.3-2. Incidence of “severely malformed vertebral column and/or ribs”. Study with M44 
and historical controls. *: statistically different from control. 
Year Fetal incidence (n/tot) Affected fetuses/litter (%) 
 control Low 
dose 
Mid 
dose 
High 
dose 
control Low 
dose 
Mid 
dose 
High 
dose 
2009 0/351 0/153 4/152 1/138 0.0 0.0 2.9* 0 
         
2009 1/184    0.4    
2009 1/156    0.4    
2010 0/251    0    
2010 0/189    0    
2011 0/232    0    
2012 0/150    0    
2012 0/214    0    
2012 0/125    0    
2013 0/194    0    
2013 1/154    0.5    
2013 0/186    0    
2013 0/126    0    
2014 1/234    0.6    
Historical 
controls 
4/2395        
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The incidence of "severely malformed vertebral column and/or ribs" in middle dose group of 
2.9% is also outside the new historical control data, while the incidence of this abnormality 
in the highest dose group no longer is outside historical control data. 
The values of 1.4% and 0.6% affected foetuses/litter for “misshapen interparietal bone” and 
for “severely malformed vertebral column and/or ribs” presented by the applicant as new 
historical controls. However, these values represent the upper range of study means for the 
respective finding and not the average over all 13 studies of the historical control.  
The new historical control value of 1.4% for “misshapen interparietal bone” is based on data 
from one study conducted more than two years after the M44 study. Furthermore, the new 
historical control value of 0.6% for “severely malformed vertebral column and/or ribs” is 
based on one study conducted in 2014, which is 5 years after the M44 study. The 2014 
study was also performed with rabbits from a new supplier. These conditions are not in line 
with central requirements in the guidelines, which state that performance date for historical 
control data should not be more than +/- two years, and studies should be performed with 
the same species, strain and supplier.    
2.2.3.4 The procedure for using historical control data 
Historical controls may be used to discuss if the higher values observed for treated animals 
than for controls in the same study may have occurred by co-incidence. There seems to have 
been a tendency that most emphasis have focused on the single highest value obtained in 
historical control groups when assessing the effect observed in the exposed animal groups.  
It is the opinion of the VKM panel that the implication of historical controls should preferably 
be assessed using statistical analysis, pending that the historical controls fulfils the quality 
criteria. An example of such analysis would be to use 2X2 contingency tables in two-sided 
Fisher Exact Test. 
When Fisher Exact Test is used for the present experiments and historical controls, the 
following results are obtained, as shown in Tables 2.2.3.4-1 and 2.2.3.4-2: 
 
Table 2.2.3.4-1. «Misshapen interparietal bone». Two-sided Fischer exact test 
Tested groups Contingency table P-value 
Control vs low dose 1/351 vs 1/153 0.52 
Control vs medium dose 1/351 vs 1/152 0.52 
Control vs high dose 1/351 vs 3/138 0.073 
   
Historical controls vs high dose 11/2746 vs 3/13 0.024* 
Actual vs historical controls 1/351 vs 10/2395 0.93 
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Such analysis of the «misshapen interparietal bone» data shows that the finding of 3 
affected foetuses in the highest dose is borderline statistically significant (P=0.073) when 
using the actual control. When including historical controls, the same finding becomes 
statistically significant (P=0.024) 
 
Table 2.2.3.4-2. “Severely malformed vertebral column and/or ribs”. Two-sided Fischer exact test 
Tested groups Contingency table P-value 
Control vs low dose 0/351 vs 0/153  
Control vs medium dose 0/351 vs 4/152 0.0087* 
Control vs high dose 0/351 vs 1/138 0.28 
   
Historical controls vs medium dose 4/2746 vs 4/152 <0.0001* 
Actual vs historical controls 0/351 vs 4/2395 0.99 
 
The Fischer Exact Test used on the data for “severely malformed vertebral column and/or 
ribs” shows that the 4 affected foetuses in the middle concentration is statistically increased 
above control, also without use of the historical controls. Again, the P-value becomes more 
significant when the historical controls are included in the analysis.  
Thus, it is the opinion of VKM’s panel on plant protection products that the provision of 
arguments and new historical controls by the applicant does not alter the previous 
conclusion; that the “misshapen interparietal bone”, and “severely malformed vertebral 
column and/or ribs” should be considered treatment related.  
The applicant argues that there is no relationship between maternal toxicity and “severely 
malformed vertebral column and/or ribs”, and that the absence of such relationship makes it 
unlikely that the increased maternal mortality will mask a dose-response relationship. 
However, the applicant does not provide any scientific evidence for these arguments. Thus, 
the VKM panel maintains its previous statement that "the lack of a dose-response 
relationship for this effect could be masked by the increased maternal mortality at the 
highest dose level."    
2.3 Re-assessment of the genotoxic potential for M44 
 Background 2.3.1
For bixafen, the data from a complete battery of in vitro and in vivo genotoxicity studies was 
reported, and based on these studies; VKM concluded that bixafen was not considered 
genotoxic (VKM, 2013a). 
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The metabolite M44 was tested for mutagenicity in four strains of Salmonella typhimurium 
(TA1535, TA1537, TA98 and TA100) and one strain of Escherichia coli (WP2 uvrA) with and 
without metabolizing S9-mix, and no indication of a response was reported.  
M44 was also tested for induction of gene mutations in Chinese hamster CHO cells with and 
without metabolic S9-mix in two independent experiments. No statistically significant 
increases in mutant frequency were observed.   
M44 was evaluated for clastogenic effects in vitro in Chinese hamster V79 cells, with and 
without metabolizing S9-mix. A mixed response was obtained in four different studies.  
Experiment 1: Increased numbers of aberrant metaphase cells with and without S9-mix. The 
increase with S9-mix was statistically significant.  
Experiment 2: Increased numbers of aberrant metaphase cells without S9-mix. The increase 
at highest dose (1.6 mg/ml) was statistically significant. 
Experiment 3 could not be evaluated.  
Experiment 4: Statistically significant increase in the number of aberrant metaphase cells 
with S9-mix. 
In the report of 2013 VKM expressed its concern on the use of “historical controls” to 
override findings in individual experiments and concluded as follows: “The presented data 
from in vitro experiments do not provide the necessary assurance that the bixafen 
metabolite M44 is negative for genotoxic activity. No data for in vivo testing of the 
metabolite have been presented. It is therefore the opinion of VKM that the submitted 
studies are not adequate to evaluate possible health risk of the metabolite M44 in 
accordance with the relevant Guidance Document.”  
 New data presented 2.3.2
The applicant has now presented data from an in vivo mouse micronucleus test in bone 
marrow cells with the bixafen metabolite M44. The study is conducted in accordance to the 
OECD guideline 474 and according to GLP.  
The mammalian in vivo micronucleus test is used for the detection of damage by the test 
item to the chromosomes or the mitotic apparatus of immature erythrocytes (so called 
polychromatic erythrocytes) in the bone marrow.  Groups of 5 male mice were treated with a 
single oral dose of the bixafen metabolite M44, dissolved in DMSO, at dose levels of 375, 750 
and 1500 mg/kg bw. Doses were selected based on a Dose-Range Finding study. The Dose-
Range finding study did not demonstrate differences between sexes in toxicity, so testing in 
a single sex in the main study is justified.  DMSO was used as vehicle control and 
cyclophosphamide and vincrine sulphate were used as positive controls for chromosome 
damage or damage to the mitotic spindle effects, respectively. The animals were sacrificed 
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24 hours following exposure. An additional group of  animals treated with  1500 mg/kg bw ,  
were sacrificed at 48 hours  Bone marrow was prepared from the 2 femora and after staining 
2000 polychromatic erythrocytes were evaluated per animal and investigated for micronuclei. 
The mature erythrocytes (so called normocytes) with and without micronuclei occurring per 
2000 polychromatic erythrocytes were also recorded. 
In a separate study on the kinetics of the bixafen metabolite M44 in mice, the bioavailability 
of the test substance in bone marrow after oral administration was demonstrated. Five hours 
after dosing low levels of M44 and its metabolites were found in plasma, blood cells and 
bone marrow.  
The incidences of micronucleated polychromatic erythrocytes per 2000 polychromatic 
erythrocytes in male mice treated with M44 were not statistically significantly different from 
those found for the vehicle control. The positive control groups differed statistically 
significantly from the vehicle control group, demonstrating the sensitivity of the system. No 
relevant inhibition of erythropoiesis determined from the ratio of polychromatic to 
normochromatic erythrocytes was detected.  
These data support the conclusion that, at the doses achieved under the conditions used in 
this study, the test item M44 did not produce chromosomal damage or damage to the mitotic 
spindle apparatus in the bone marrow of mice. 
It is the opinion of VKM that this in vivo study overrides the results of the in vitro 
clastogenicity study. Taken together it is the opinion of VKM that under the conditions 
studied M44 should be considered as non-genotoxic. 
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3 Conclusions  
 
On the assessment of genotoxic properties of the M44 metabolite of bixafen, one 
of the active ingredients of Aviator Xpro EC 225  
It is the view of VKM Panel on Plant Protection Products that the new in vivo mouse 
micronucleus study, supplemented together with a separate study demonstrating 
bioavailability, overrides the results of the in vitro clastogenicity studies. Taken together, it is 
the opinion of VKM that under the conditions studied, M44 should be considered as non-
genotoxic. 
On the assessment of the relevance of the foetal malformations in M44 exposed 
animals 
VKMs Panel on Plant Protection products has assessed the arguments and new historical 
control data presented by the applicant, intended to show that metabolite M44 is not 
teratogenic. It is however the opinion of the Panel that the arguments and the new historical 
data provided by the applicant do not alter the panel’s previous conclusion; that the 
malformations observed in rabbits exposed to the metabolite M44 should be considered 
treatment related.    
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